$XBIO
Xenetic Biosciences, Inc.

2024 Q4 Form 10-Q Financial Statement

#000168316824007903 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $614.2K
YoY Change 0.5%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $745.7K
YoY Change 0.77%
% of Gross Profit
Research & Development $368.0K
YoY Change -63.94%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.114M
YoY Change -36.64%
Operating Profit -$499.5K
YoY Change -56.44%
Interest Expense $61.30K
YoY Change -31.89%
% of Operating Profit
Other Income/Expense, Net $62.80K
YoY Change -31.09%
Pretax Income -$436.7K
YoY Change -58.8%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$436.7K
YoY Change -58.63%
Net Earnings / Revenue -71.09%
Basic Earnings Per Share -$0.28
Diluted Earnings Per Share -$0.28
COMMON SHARES
Basic Shares Outstanding 1.542M shares 1.542M shares
Diluted Shares Outstanding 1.542M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.840M
YoY Change -30.07%
Cash & Equivalents $6.840M
Short-Term Investments
Other Short-Term Assets $188.1K
YoY Change -87.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $7.028M
YoY Change -37.57%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.018M
YoY Change 44.56%
Total Long-Term Assets $1.018M
YoY Change 44.56%
TOTAL ASSETS
Total Short-Term Assets $7.028M
Total Long-Term Assets $1.018M
Total Assets $8.046M
YoY Change -32.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $243.3K
YoY Change -45.75%
Accrued Expenses $766.1K
YoY Change 23.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.009M
YoY Change -5.53%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.009M
Total Long-Term Liabilities $0.00
Total Liabilities $1.009M
YoY Change -5.53%
SHAREHOLDERS EQUITY
Retained Earnings -$196.1M
YoY Change 2.12%
Common Stock $1.545K
YoY Change 0.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $7.037M
YoY Change
Total Liabilities & Shareholders Equity $8.046M
YoY Change -32.73%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$436.7K
YoY Change -58.63%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$459.0K
YoY Change -51.68%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -459.0K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -459.0K
YoY Change -51.68%
FREE CASH FLOW
Cash From Operating Activities -$459.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.89
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.89
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1541722 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1541722 shares
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001534525
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37937
dei Entity Registrant Name
EntityRegistrantName
XENETIC BIOSCIENCES, INC.
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01701
CY2023Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
611174 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1851464 usd
CY2024Q3 us-gaap Revenues
Revenues
614243 usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-2952962
dei Entity Address Address Line1
EntityAddressAddressLine1
945 Concord Street
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
778-7720
dei Trading Symbol
TradingSymbol
XBIO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1542139 shares
CY2024Q3 us-gaap Cash
Cash
6839560 usd
CY2023Q4 us-gaap Cash
Cash
8983046 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
188088 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
603828 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
7027648 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
9586874 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1018352 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1018352 usd
CY2024Q3 us-gaap Assets
Assets
8046000 usd
CY2023Q4 us-gaap Assets
Assets
10605226 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
243343 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
240832 usd
CY2024Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
766064 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
568753 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1009407 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
809585 usd
CY2024Q3 us-gaap Liabilities
Liabilities
1009407 usd
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 XBIO Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
XBIO Exercise Of Purchase Warrants Value
ExerciseOfPurchaseWarrantsValue
usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
XBIO Stock Issued During Period Value Reverse Stock Splits
StockIssuedDuringPeriodValueReverseStockSplits
usd
dei Entity Address City Or Town
EntityAddressCityOrTown
Framingham
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023Q4 us-gaap Liabilities
Liabilities
809585 usd
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1544840 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1543385 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1542139 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1540684 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1545 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1544 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208200640 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
208053935 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-196139950 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-193234196 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
253734 usd
CY2024Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5281180 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7036593 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
9795641 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8046000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10605226 usd
CY2024Q3 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
614243 usd
us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
1868023 usd
CY2023Q3 us-gaap Revenues
Revenues
611174 usd
us-gaap Revenues
Revenues
1851464 usd
us-gaap Revenues
Revenues
1868023 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
367985 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1020618 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2246077 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2519137 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
745731 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
737241 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2710670 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2608934 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1113716 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1757859 usd
us-gaap Operating Expenses
OperatingExpenses
4956747 usd
us-gaap Operating Expenses
OperatingExpenses
5128071 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-499473 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1146685 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3105283 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3260048 usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1504 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-666 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1535 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24976 usd
CY2024Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
61298 usd
CY2023Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
91796 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
197994 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
272000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
62802 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
91130 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
199529 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
296976 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-436671 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1055555 usd
us-gaap Net Income Loss
NetIncomeLoss
-2905754 usd
us-gaap Net Income Loss
NetIncomeLoss
-2963072 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.94
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.94
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1532600 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1532600 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1541070 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1541070 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1524717 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1524717 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
7445728 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
27536 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-436671 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7036593 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
9795641 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
146706 usd
us-gaap Net Income Loss
NetIncomeLoss
-2905754 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
7036593 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11877858 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
70266 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1055555 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10892569 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13647134 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
208507 usd
us-gaap Net Income Loss
NetIncomeLoss
-2963072 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
10892569 usd
us-gaap Net Income Loss
NetIncomeLoss
-2905754 usd
us-gaap Net Income Loss
NetIncomeLoss
-2963072 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
146706 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
208507 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-415740 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
924468 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-0 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-362500 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
199822 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-4659 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2143486 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3321192 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2143486 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3321192 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8983046 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13097265 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6839560 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9776073 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-10 basis
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
27536 usd
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
70266 usd
us-gaap Share Based Compensation
ShareBasedCompensation
146706 usd
us-gaap Share Based Compensation
ShareBasedCompensation
208507 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
40600000 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
39700000 usd
CY2024Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001683168-24-007903-index-headers.html Edgar Link pending
0001683168-24-007903-index.html Edgar Link pending
0001683168-24-007903.txt Edgar Link pending
0001683168-24-007903-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xbio-20240930.xsd Edgar Link pending
xenetic_ex3101.htm Edgar Link pending
xenetic_ex3102.htm Edgar Link pending
xenetic_ex3201.htm Edgar Link pending
xenetic_i10q-093024.htm Edgar Link pending
xbio-20240930_cal.xml Edgar Link unprocessable
xbio-20240930_def.xml Edgar Link unprocessable
xbio-20240930_lab.xml Edgar Link unprocessable
xbio-20240930_pre.xml Edgar Link unprocessable
xenetic_i10q-093024_htm.xml Edgar Link completed